A trimeric, V2-deleted HIV-1 envelope glycoprotein vaccine elicits potent neutralizing antibodies but limited breadth of neutralization in human volunteers.

Publication Type:

Journal Article

Source:

The Journal of infectious diseases, Volume 203, Issue 8, p.1165-73 (2011)

Keywords:

2011, Adult, AIDS Vaccines, Antibodies, Neutralizing, Antibody Specificity, CD4-Positive T-Lymphocytes, Clinical Research Division, DNA, Viral, env Gene Products, Human Immunodeficiency Virus, Epitope Mapping, HIV Infections, HIV-1, Humans, Immunity, Cellular, Immunization, Secondary, Public Health Sciences Division, Vaccine and Infectious Disease Division, Vaccines, Synthetic

Abstract:

A key missing element in the development of a successful human immunodeficiency virus (HIV) vaccine is an immunogen that can generate broadly cross-neutralizing antibodies against primary isolates of the virus.